How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 69.1 | 69.1 | 68.3 | 67.6 | 67.6 | 67.6 | -1.4 |
| Healthcare | 25.6 | 25.6 | 25.8 | 26.6 | 26.6 | 26.6 | +1.0 |
| Chemicals | 3.6 | 3.6 | 4.4 | 4.5 | 4.5 | 4.5 | +0.9 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 9.20% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| DIVISLAB | Pharma | 8.02% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| LUPIN | Pharma | 5.45% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| MAXHEALTH | Healthcare | 5.26% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| ASTERDM | Healthcare | 5.18% | 10 | 4 | 8 | 3 | 1 | 1/2 | +15.1% |
| CIPLA | Pharma | 4.92% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| ACUTAAS | Chemicals | 4.50% | 8 | 10 | 2 | 5 | 1 | 0/2 | +43.1% |
| ALKEM | Pharma | 4.36% | 9 | 8 | 8 | 10 | 6 | 1/2 | +0.5% |
| ANTHEM | Pharma | 4.15% | 7 | 10 | 3 | 5 | 2 | 0/2 | -2.3% |
| IPCALAB | Pharma | 3.50% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
| FORTIS | Healthcare | 3.41% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| GLENMARK | Pharma | 3.28% | 6 | 9 | 10 | 4 | 3 | 0/2 | +1.5% |
| LAURUSLABS | Pharma | 3.17% | 8 | 9 | 4 | 4 | 1 | 0/2 | +34.0% |
| KIMS | Healthcare | 3.16% | 7 | 3 | 7 | 4 | 1 | 0/2 | +19.2% |
| MEDANTA | Healthcare | 3.08% | 9 | 9 | 6 | 8 | 2 | 0/2 | +23.2% |
| NEULANDLAB | Healthcare | 2.98% | 10 | 10 | 5 | 10 | 2 | 1/2 | +27.4% |
| VIJAYA | Pharma | 2.70% | 8 | 10 | 4 | 2 | 1 | 0/2 | +37.0% |
| ZYDUSLIFE | Pharma | 2.50% | 10 | 10 | 10 | 10 | 6 | 1/2 | +23.3% |
| WOCKPHARMA | Pharma | 2.44% | 7 | 3 | 3 | 1 | 2 | 0/2 | +33.0% |
| SAILIFE | Healthcare | 1.78% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| ERIS | Pharma | 1.61% | 5 | 7 | 5 | 6 | 6 | 0/2 | +1.0% |
| JUBLPHARMA | Pharma | 1.34% | 5 | 2 | 3 | 6 | 6 | 0/2 | +5.5% |
| BIOCON | Pharma | 1.33% | 6 | 1 | 10 | 5 | 3 | 0/2 | +12.5% |
| GLAND | Pharma | 1.19% | 9 | 8 | 6 | 6 | 4 | 0/2 | +38.5% |
| COHANCE | Healthcare | 0.46% | 4 | 5 | 4 | 10 | 4 | 0/2 | +13.2% |
Performance · 2.8y
Over the last 2.8 years ₹100 in the fund grew to ₹207 (+107%), vs ₹134 for Nifty 500 (+34%) and ₹123 for Nifty 50 (+23%). Its relative-strength line ended at 168 vs Nifty 50 and 155 vs Nifty 500 — above 100, sustained outperformance.